Compare Strategy Inc. (MSTR) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Strategy Inc. vs Pfizer Inc — how do they compare? Strategy Inc. trades at $153.71 (market cap $60.40B), while Pfizer Inc trades at $27.78 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 2.6× Strategy Inc.'s market cap, and Pfizer Inc pays a 6.18% dividend while Strategy Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Strategy Inc. for 112 Days and Pfizer Inc for 158 Days on average.
| MSTR | PFE | |
|---|---|---|
Market Cap | $60.40B | $158.56B |
Volume | 23,421,830 | 44,138,282 |
Sector | Technology | Health |
52-Week High | $320.29 | $29.02 |
52-Week Low | $82.31 | $23.67 |
Typical Hold Time | 112 Days | 158 Days |
Enterprise Value | $79.16B | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTR stock trades at $153.37, down 6.79% today, reflecting volatility despite a bullish technical signal. The company reported a net loss of $3.85B in 2025 with a negative net income margin of -6,102.96%, though revenue grew slightly to $477.23M. Analyst consensus remains optimistic with a $252 price target, but earnings misses in recent quarters highlight operational challenges.
The outlook hinges on improving profitability and Bitcoin market stability, offering upside if earnings rebound. Key risks include persistent losses, high debt, and sensitivity to macroeconomic factors. Investors should weigh analyst optimism against fundamental weaknesses before considering a position.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
